Michael Gelband’s Harvard Bioscience HBIO Stock Holding History

Michael Gelband’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,580	Closed	-$110K	–	2343
2021 Q3	$110K	Buy	1,580 +154	+11%	+$12.3K	﹤0.01%	1889
2021 Q2	$119K	Buy	+1,426	New	+$101K	﹤0.01%	2113
2019 Q3	–	Sell	-1,005	Closed	-$20K	–	1454
2019 Q2	$20K	Buy	+1,005	New	+$29.4K	﹤0.01%	1059

Other funds holding HBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.46B AUM 78.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's HBIO Position: Q4 2021 in Review

Michael Gelband sold out of Harvard Bioscience (HBIO) in Q4 2021, closing a stake of 1,580 shares — an estimated $110K sold.

Michael Gelband first reported a position in HBIO in Q2 2019 and held it in 3 quarters. The position peaked at $119K in Q2 2021. 103 funds tracked by Wall St. Rank hold HBIO as of Q4 2021.

Michael Gelband reported no remaining Harvard Bioscience position as of Q4 2021 after selling out during the quarter.
Michael Gelband sold 1,580 Harvard Bioscience shares in Q4 2021, an estimated $110K.
Michael Gelband first reported a position in Harvard Bioscience in Q2 2019 and held it in 3 quarters.
Michael Gelband's Harvard Bioscience position peaked at $119K in Q2 2021.
103 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.